Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 307

1.

Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue.

Diem K, Magaret A, Klock A, Jin L, Zhu J, Corey L.

J Virol Methods. 2015 Jun 12;222:117-121. doi: 10.1016/j.jviromet.2015.06.004. [Epub ahead of print]

PMID:
26073660
2.

A dual modality HSV-2 vaccine for preventing genital herpes using glycoproteins C and D subunit antigens to induce potent antibody responses and adenovirus vectors containing capsid and tegument proteins as T cell immunogens.

Awasthi S, Mahairas GG, Shaw CE, Huang ML, Koelle DM, Posavad C, Corey L, Friedman HM.

J Virol. 2015 Jun 3. pii: JVI.01089-15. [Epub ahead of print]

PMID:
26041292
3.

Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant.

Campbell AP, Guthrie KA, Englund JA, Farney RM, Minerich EL, Kuypers J, Corey L, Boeckh M.

Clin Infect Dis. 2015 Jul 15;61(2):192-202. doi: 10.1093/cid/civ272. Epub 2015 Apr 5.

PMID:
25847977
4.

Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices.

Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, Flowers ME, Corey L, Boeckh M.

Clin Infect Dis. 2015 Jul 1;61(1):31-9. doi: 10.1093/cid/civ215. Epub 2015 Mar 16.

PMID:
25778751
5.

Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection.

Melvin AJ, Mohan KM, Schiffer JT, Drolette LM, Magaret A, Corey L, Wald A.

J Pediatr. 2015 Apr;166(4):827-33. doi: 10.1016/j.jpeds.2014.11.011. Epub 2014 Dec 6.

PMID:
25491092
6.

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.

Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.

PMID:
25454855
7.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

8.

Reevaluating HIV vaccine clinical trials policy for infants.

Gray GE, Corey L.

J Infect Dis. 2015 Feb 15;211(4):501-3. doi: 10.1093/infdis/jiu445. Epub 2014 Aug 27. No abstract available.

PMID:
25170103
9.

Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa.

Perti T, Nyati M, Gray G, De Bruyn G, Selke S, Magaret A, Huang ML, Velaphi S, Corey L, Wald A.

Infect Dis Obstet Gynecol. 2014;2014:258291. doi: 10.1155/2014/258291. Epub 2014 May 20.

10.

Nuclear factor kappa B is required for the production of infectious human herpesvirus 8 virions.

Blattman NN, Lagunoff M, Blattman JN, Corey L.

Front Microbiol. 2014 Apr 4;5:129. doi: 10.3389/fmicb.2014.00129. eCollection 2014.

11.

Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy.

Gantt S, Cattamanchi A, Krantz E, Magaret A, Selke S, Kuntz SR, Huang ML, Corey L, Wald A, Casper C.

J Clin Virol. 2014 Jun;60(2):127-32. doi: 10.1016/j.jcv.2014.03.002. Epub 2014 Mar 13.

12.

One shot forward for HIV prevention.

Corey L, McElrath MJ.

Nat Med. 2014 Mar;20(3):241-2. doi: 10.1038/nm.3503. No abstract available.

PMID:
24603794
13.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

14.

Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, Corey L.

J Virol. 2014 May;88(9):4921-31. doi: 10.1128/JVI.03285-13. Epub 2014 Feb 19.

15.

Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines".

Knipe DM, Corey L, Cohen JI, Deal CD.

Vaccine. 2014 Mar 20;32(14):1561-2. doi: 10.1016/j.vaccine.2014.01.052. Epub 2014 Jan 28. No abstract available.

PMID:
24480025
16.

Helicase-primase inhibitor pritelivir for HSV-2 infection.

Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A.

N Engl J Med. 2014 Jan 16;370(3):201-10. doi: 10.1056/NEJMoa1301150.

17.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

18.

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Schiffer JT, Swan DA, Corey L, Wald A.

Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9. doi: 10.1128/AAC.01114-13. Epub 2013 Sep 9.

19.

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.

Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Nov 1;208(9):1366-74. doi: 10.1093/infdis/jit333. Epub 2013 Jul 30.

20.

HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James I, Halloran ME, Thomas PG, Corey L.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13492-7. doi: 10.1073/pnas.1221555110. Epub 2013 Jul 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk